// App-Quantinova.ai

11502 : Final results of ENLIVEN: A global, double-blind, randomized, placebo-controlled, phase 3 study of pexidartinib in advanced tenosynovial giant cell tumor (TGCT).

Researchers

Presenter

  • William D. Tap

Principal Investigators

  • Silvia Stacchiotti

  • Emanuela Palmerini

  • Stefano Ferrari

  • Jayesh Desai

  • Sebastian Bauer

  • Jean-Yves Blay

  • Thierry Alcindor

  • Kristen N. Ganjoo

  • Javier Martin Broto

  • Christopher W. Ryan

  • Dale Edward Shuster

  • Ling Zhang

  • Qiang Wang

  • Henry Hsu

  • Paul S. Lin

  • Sandra Tong

  • Andrew J. Wagner

Medical Centers

  • Department of Surgery, Gynecologic Service, Memorial Sloan-Kettering Cancer Center, New York, NY

  • Leiden University Medical Centre, Leiden, Netherlands

  • Department of Medical Oncology, IRCCS Fondazione Istituto Nazionale dei Tumori, Milan, Italy

  • Istituto Ortopedico Rizzoli, Bologna, Italy

  • Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Melbourne, Australia

  • West German Cancer Center, University Hospital, Essen, Germany

  • Centre Leon Berard, Lyon, France

  • McGill University Health Centre, Montreal, QC, Canada

  • Stanford University Cancer Institute, Stanford, CA

  • Virgen del Rocio University Hospital, Institute of Biomedicine Research (IBIS)/CSIC/Universidad de Sevilla, Seville, Spain

  • Oregon Health & Science University, OHSU Knight Cancer Institute, Portland, OR

  • Daiichi Sankyo Pharma Dev, Edison, NJ

  • Daiichi Sankyo, Inc., Edison, NJ

  • Plexxikon Inc, Berkeley, CA

  • Dana-Farber Cancer Institute, Boston, MA

Locations

  • Canada

  • Italy

  • Netherlands

  • Germany

  • Spain

  • Australia

  • United States

  • France

Companies

  • Daiichi Sankyo Inc.

  • Plexxikon Inc.

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • N/A

Biomarkers

  • N/A

Drug/Treatment

  • Pexidartinib

  • X-22

Outcome

  • Positive

Study Design

  • Randomized

  • Placebo Control

  • Double Blind/Blinded

  • Open Label

  • Controlled

Phase

  • III

Study Id's

  • NCT02371369

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved